Philip C. Bourne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Philip C. Bourne has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Blaine H. M. Mooers
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
1 shared publication - Jeng Shi Kong
Department of Pathology University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA
1 shared publication - Kritisha Bhandari
Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
1 shared publication - Wang‐Ting Tina Ho
Department of Pathology University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA
1 shared publication - Wei-Qun Ding
Department of Pathology University of Oklahoma College of Medicine Oklahoma City Oklahoma USA
1 shared publication
Latest Publications
- 6 January 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (1) , e70287
Arginine demethylation of Serine/Arginine‐rich splicing factor 1 enhances miRNA enrichment in small extracellular vesicles derived from pancreatic ductal adenocarcinoma cells
Small extracellular vesicles (sEVs) are enriched in certain miRNAs, impacting the progression of pancreatic ductal adenocarcinoma (PDAC). The mechanisms involved in the selective sEV miRNA enrichment remain to be elucidated. We recently reported that Serine/Arginine‐rich splicing factor 1 (SRSF1) regulates selective sEV miRNA enrichment in PDAC cells. SRSF1 is an onco‐protein that is overexpressed in PDAC, and its function is dictated by posttranslational modifications such as phosphorylation and arginine methylation. The objective of this study was to examine the role of phosphorylation and arginine methylation in SRSF1‐mediated sEV miRNA enrichment in PDAC cells. Treatment of PDAC cells with the protein arginine methyltransferase inhibitors AMI‐5 and EPZ015666, but not with the phosphorylation inhibitor SRPIN340, selectively enhanced the level of sEV miR‐1246, a miRNA known to be highly enriched in PDAC sEVs. Consistently, overexpression of the mutant SRSF1 with the three arginine residues R93, R97, and R109 being replaced with lysinaugmented sEV miR‐1246 levels in both wild‐type and SRSF1‐knockdown PANC‐1 cells. Interestingly, the binding of SRSF1 to miR‐1246 was significantly reduced in PDAC cells overexpressing the mutant SRSF1, which was further confirmed using purified wild‐type and the mutant SRSF1 proteins. We demonstrate that arginine demethylation of SRSF1 reduces SRSF1‐miRNA binding in PDAC cells and enhances selective sEV miRNA enrichment, providing novel insight into SRSF1‐mediated sEV miRNA enrichment in PDAC cells and opening up new avenues of investigation on the biology and function of extracellular vesicles in PDAC.
- 6 January 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (1) , e70287
Arginine demethylation of Serine/Arginine‐rich splicing factor 1 enhances miRNA enrichment in small extracellular vesicles derived from pancreatic ductal adenocarcinoma cells
Small extracellular vesicles (sEVs) are enriched in certain miRNAs, impacting the progression of pancreatic ductal adenocarcinoma (PDAC). The mechanisms involved in the selective sEV miRNA enrichment remain to be elucidated. We recently reported that Serine/Arginine‐rich splicing factor 1 (SRSF1) regulates selective sEV miRNA enrichment in PDAC cells. SRSF1 is an onco‐protein that is overexpressed in PDAC, and its function is dictated by posttranslational modifications such as phosphorylation and arginine methylation. The objective of this study was to examine the role of phosphorylation and arginine methylation in SRSF1‐mediated sEV miRNA enrichment in PDAC cells. Treatment of PDAC cells with the protein arginine methyltransferase inhibitors AMI‐5 and EPZ015666, but not with the phosphorylation inhibitor SRPIN340, selectively enhanced the level of sEV miR‐1246, a miRNA known to be highly enriched in PDAC sEVs. Consistently, overexpression of the mutant SRSF1 with the three arginine residues R93, R97, and R109 being replaced with lysinaugmented sEV miR‐1246 levels in both wild‐type and SRSF1‐knockdown PANC‐1 cells. Interestingly, the binding of SRSF1 to miR‐1246 was significantly reduced in PDAC cells overexpressing the mutant SRSF1, which was further confirmed using purified wild‐type and the mutant SRSF1 proteins. We demonstrate that arginine demethylation of SRSF1 reduces SRSF1‐miRNA binding in PDAC cells and enhances selective sEV miRNA enrichment, providing novel insight into SRSF1‐mediated sEV miRNA enrichment in PDAC cells and opening up new avenues of investigation on the biology and function of extracellular vesicles in PDAC.